Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial
Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial
复制标题
DOI：
10.1200/jco.2008.18.1024
复制
发表时间：
2009-03-10
影响因子：
45.3
通讯作者：
Vogel, Charles
中科院分区：
文献类型：
--
作者：
Hugh, Judith;Hanson, John;Vogel, Charles
PurposeTo研究在一项含紫杉醇方案的临床试验中，通过免疫组化检测亚型淋巴结阳性早期乳腺癌的预后和预测意义。和环磷酰胺（FAC）用于可手术的淋巴结阳性乳腺癌。患者按肿瘤特征分类为（1）三阴性（雌激素受体[ER]阴性，孕酮受体[PR]阴性，HER 2/neu [HER 2]阴性），（2）HER 2（HER 2阳性、ER阴性、PR阴性），（3）管腔B（ER阳性和/或PR阳性以及HER 2阳性和/或Ki 67（高）），和（4）管腔A（ER阳性和/或PR阳性而非HER 2阳性或Ki 67（高）），并评估其预后意义和对辅助化疗的反应。（14.5%）、HER 2（8.5%）、管腔B（61.1%）和管腔A（15.9%）。3年无病生存率（以管腔B为参照的P值）为67%（P
PurposeTo investigate the prognostic and predictive significance of subtyping node-positive early breast cancer by immunohistochemistry in a clinical trial of a docetaxel-containing regimen.MethodsPathologic data from a central laboratory were available for 1,350 patients (91%) from the BCIRG 001 trial of docetaxel, doxorubicin, and cyclophosphamide (TAC) versus fluorouracil, doxorubicin, and cyclophosphamide (FAC) for operable node-positive breast cancer. Patients were classified by tumor characteristics as (1) triple negative (estrogen receptor [ER]-negative, progesterone receptor [PR]-negative, HER2/neu [HER2]-negative), (2) HER2 (HER2-positive, ER-negative, PR-negative), (3) luminal B (ER-positive and/or PR-positive and either HER2-positive and/or Ki67(high)), and (4) luminal A ( ER-positive and/or PR-positive and not HER2-positive or Ki67(high)), and assessed for prognostic significance and response to adjuvant chemotherapy.ResultsPatients were subdivided into triple negative (14.5%), HER2 (8.5%), luminal B (61.1%), and luminal A (15.9%). Three-year disease-free survival (DFS) rates (P values with luminal B as referent) were 67% (P